

MAR. 8. 2005 9:28AM AVENTIS US PAT DEPT
TO: US USPTO GENERAL

RECEIVED
CENTRAL FAX CENTER

NO. 3077 P. 1

MAR 08 2005


PTO/SB/21 (09-04)


Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	798466/10	
	Filing Date	March 09, 2004	
	First Named Inventor	Joachim BRENDDEL et al.	
	Art Unit	1625	
	Examiner Name	MORRIS, Patricia L.	
Total Number of Pages In This Submission	4	Attorney Docket Number	DEAV2003/0024 US NP

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input checked="" type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Reply to Missing Parts/Incomplete Application	<input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53		
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm Name	AVENTIS PHARMACEUTICALS INC.		
Signature			
Printed name	Joseph D. Rossi		
Date	March 08, 2005	Reg. No.	47,038

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: (USPTO FAX NO. 703-872-9308; Total No. of Pages Transmitted: 4)			
Signature			
Typed or printed name	Paul Irvine	Date	March 08, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
BRENDDEL, et al.

Examiner: P. Morris

RECEIVED
CENTRAL FAX CENTER

Art Unit: 1625

MAR 08 2005

Application No.: 10/796,466

Filed: March 9, 2004

Title: 2-(BUTYL-1-SULFONYLAMINO)-N-
[1(R)-(6-METHOXYPYRIDIN-3-
YL)PROPYL] BENZAMIDE, ITS USE
AS A MEDICAMENT, AND
PHARMACEUTICAL
PREPARATIONS COMPRISING IT

CERTIFICATE OF TRANSMISSION
I hereby certify that this correspondence is being transmitted
via facsimile to the Commissioner for Patents, P.O. Box 1450,
Alexandria, VA 22313-1450, at 703-872-9306, on

March 8, 2005
Date of Deposit

Paul Irvine
Signature

REPLY PUSUANT TO 37 C.F.R. § 1.111

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

This paper is in response to the Office Action dated February 10, 2005 ("the Action"), in which a restriction requirement was issued in connection with the above-identified patent application. Reconsideration of the Examiner's action in the present application is requested respectfully in view of the following remarks.

The Office Action requires restriction to one of the following groups under 35 U.S.C. §121:

- I. Claims 1-4, and 7, drawn to compounds, classified in class 546, subclass 300.
- II. Claim 5, drawn to compositions containing an unknown additional active ingredient, classified in class 514, various subclasses.
- III. Claim 6, drawn to an intermediate, classified in class 546, subclass 290.

Best Available Copy